Literature DB >> 32377210

The Efficacy of Probiotics for Treatment of Bipolar Disorder-Type 1: A Randomized, Double-Blind, Placebo Controlled Trial.

Mahin Eslami Shahrbabaki1, Saleheh Sabouri2, Abdolreza Sabahi3, Delaram Barfeh4, Parisa Divsalar3, Mahdi Esmailzadeh5, Atefeh Ahmadi6.   

Abstract

Objective: Bipolar disorders are among the most common chronic mental disorders. Despite the recent improvement in controlling psychiatric disorders, treatment of bipolar disorders remains a challenge. The aim of this study was to determine the effect of consuming probiotics in patients with bipolar disorder-type 1 compared to the placebo group. Method : This was a permuted blocked randomized clinical trial conducted in Shahid Beheshti mental hospital in Kerman, Iran, from October 2017 to October 2018. Two psychiatrists diagnosed and hospitalized all 38 patients with type 1 bipolar disorder based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Using blind randomized blocking method size 4, patients were divided into 2 groups of placebo and probiotic. Young Mania Rating Scale (YMRS) and Hamilton's Depression Rating Scale (HDRS) were completed at the beginning, week 4, and week 8 of the study by a psychiatry resident. Independent t test, Mann-Whitney and repeated measures ANOVA tests were used. Data were analyzed using SPSS software version 20.
Results: There was no significant difference between the 2 groups in age, sex, and severity of mania and depression. Consumption of probiotics reduced the scores of YMRS and HDRS over time in the probiotic group more than the placebo group, but it was not significant.
Conclusion: Consumption of probiotics had non-significant effects on improvement and treatment of bipolar type 1 patients. It is suggested that future studies be conducted with different probiotic microbial strains and longer period of treatment.
Copyright © Psychiatry & Psychology Research Center, Tehran University of Medical Sciences.

Entities:  

Keywords:  Bipolar Disorder; Placebo; Probiotic; Randomized Controlled Trials

Year:  2020        PMID: 32377210

Source DB:  PubMed          Journal:  Iran J Psychiatry        ISSN: 1735-4587


  8 in total

Review 1.  Role of the gut microbiome in three major psychiatric disorders.

Authors:  Jenny Borkent; Magdalini Ioannou; Jon D Laman; Bartholomeus C M Haarman; Iris E C Sommer
Journal:  Psychol Med       Date:  2022-05-04       Impact factor: 10.592

2.  A Systematic Review of Nutraceuticals for the Treatment of Bipolar Disorder.

Authors:  Melanie M Ashton; Bianca E Kavanagh; Wolfgang Marx; Michael Berk; Jerome Sarris; Chee H Ng; Malcolm Hopwood; Lana J Williams; Olivia M Dean
Journal:  Can J Psychiatry       Date:  2020-09-23       Impact factor: 4.356

Review 3.  Inflammation-driven brain and gut barrier dysfunction in stress and mood disorders.

Authors:  Ellen Doney; Alice Cadoret; Laurence Dion-Albert; Manon Lebel; Caroline Menard
Journal:  Eur J Neurosci       Date:  2021-05-17       Impact factor: 3.698

4.  The Role of the Gut Microbiota in the Development and Progression of Major Depressive and Bipolar Disorder.

Authors:  Tom Knuesel; M Hasan Mohajeri
Journal:  Nutrients       Date:  2021-12-23       Impact factor: 5.717

5.  The effect of interventions targeting gut microbiota on depressive symptoms: a systematic review and meta-analysis.

Authors:  Mark Hofmeister; Fiona Clement; Scott Patten; Joyce Li; Laura E Dowsett; Brenlea Farkas; Liza Mastikhina; Oluwaseun Egunsola; Ruth Diaz; Noah C A Cooke; Valerie H Taylor
Journal:  CMAJ Open       Date:  2021-12-21

Review 6.  Gut Microbiota - A Potential Contributor in the Pathogenesis of Bipolar Disorder.

Authors:  Peifen Zhang; Lingzhuo Kong; Huimin Huang; Yanmeng Pan; Danhua Zhang; Jiajun Jiang; Yuting Shen; Caixi Xi; Jianbo Lai; Chee H Ng; Shaohua Hu
Journal:  Front Neurosci       Date:  2022-03-23       Impact factor: 4.677

Review 7.  A systematic review of gut microbiota composition in observational studies of major depressive disorder, bipolar disorder and schizophrenia.

Authors:  A J McGuinness; J A Davis; S L Dawson; A Loughman; F Collier; M O'Hely; C A Simpson; J Green; W Marx; C Hair; G Guest; M Mohebbi; M Berk; D Stupart; D Watters; F N Jacka
Journal:  Mol Psychiatry       Date:  2022-02-22       Impact factor: 13.437

Review 8.  Recent developments in the probiotics as live biotherapeutic products (LBPs) as modulators of gut brain axis related neurological conditions.

Authors:  Duygu Ağagündüz; Feray Gençer Bingöl; Elif Çelik; Özge Cemali; Çiler Özenir; Fatih Özoğul; Raffaele Capasso
Journal:  J Transl Med       Date:  2022-10-08       Impact factor: 8.440

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.